Recipharm divests Portuguese distribution business and ophthalmology company for approximately EUR 31 million
Recipharm AB (publ) today announces the divestment of the Medicamenta business unit, conducted within the subsidiary Lusomedicamenta – Sociedade Técnica Farmacêutica, S.A., to Laboratório Medinfar - Produtos Farmacêuticos. In a separate transaction, 100 per cent of the shares in the subsidiary DAVI II Farmacêutica, S.A. (“DAVI”) has been divested to PIHEX - INVESTIMENTOS IMOBILIÁRIOS, LDA. Recipharm’s Contract Manufacturing activities in Portugal will remain unchanged. The Medicamenta business unit focuses on cardiovascular disease, respiratory diseases and metabolic diseases with